A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Community-acquired Pneumonia in Pediatric Subjects Ages 8 to 17 Years Old.

Trial Profile

A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Community-acquired Pneumonia in Pediatric Subjects Ages 8 to 17 Years Old.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Tigecycline (Primary) ; Aminoglycosides; Ceftriaxone; Clarithromycin; Metronidazole
  • Indications Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections
  • Focus Therapeutic Use
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 06 Jan 2017 This trial has been completed in Hungary (on 2014-12-12), according to European Clinical Trials Database
    • 21 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top